Abstract
Background Multiple sclerosis (MS) is an inflammatory disease characterized by demyelination and neuro-axonal degeneration in the central nervous system. Except for neurofilament light protein, identification of biomarkers has been difficult to assess in the blood, presumably due partly to sensitivity. To detect traces of disease activities in the periphery and identify low-abundance protein biomarkers, this study conducts an exploratory examination of the plasma proteome of MS using proximity extension technology, a high-sensitivity multiplex PCR-based immunoassay.
Methods A case-control cohort consisting of 52 MS cases (relapsing-remitting=30, progressive=22) and 17 healthy controls were enrolled at the Karolinska University Hospital. EDTA plasma was analyzed for 1157 unique protein targets across thirteen proximity extension assays. Protein associations to disease outcomes and related clinical measures were assessed using a multivariable linear regression model corrected for sex and age at sampling.
Results AHCY and CHR levels were higher among MS cases than controls, while FABP2 was lower among those with relapsing-remitting disease than controls (Pdiscovery<0.05, Preplication<0.05), although not significant after multiple test corrections. Furthermore, PTN and CYR61 levels were higher in progressive MS than in relapsing-remitting disease (P<0.0002, PFDR<0.05), and CRNN and CXCL13 were associated with more severe disability at sampling (P<0.0001, PFDR<0.05), independent of disease course. CTSF was positively correlated with disease duration (P=4.1×10−5, PFDR=0.044), while RRM2B level correlated with intrathecal immunoglobulin production (IgG Index) in relapsing-remitting MS (P=1.7×10−5, PFDR=0.018).
Conclusion We provide several candidates for characterizing MS, particularly progressive disease, which may help monitor disease progression and treatment response in a clinical setting.
Competing Interest Statement
JH and IK have nothing to declare. FP has received research grants from Janssen, Merck KGaA and UCB, and fees for serving on DMC in clinical trials with Chugai, Lundbeck and Roche, and fees for expert witness statement for Novartis. TO has received lecture and/or advisory board honoraria, and unrestricted MS research grants from Astrazeneca, Biogen, Novartis, Merck, Roche, Almirall and Genzyme.
Funding Statement
This work was supported by the Swedish Research Council (Grant VR 2020-01638, 2020-02700), The Swedish Brain foundation, the Swedish Multiple Sclerosis Research Foundation, an endMS Doctoral Studentship (EGID:3045) from the Multiple Sclerosis Society of Canada and NEURO Sweden. J.H. and I.K. were partially supported by Horizon 2020 MultipleMS Grant 733161.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Stockholm Regional Ethical Review Board (no. 2009/2107-31/2, 2015/1280-32), and all participants have provided informed and written consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Primary associations are provided in the supplements with all data provided in doi:10.17605/OSF.IO/9QT5H. Raw data and analytical scripts can be made available given reasonable request.
Abbreviations
- AHCY
- adenosylhomocysteinase
- CRH
- Corticotropin-releasing hormone
- CRNN
- Cornulin
- CSF
- Cerebrospinal fluid
- CXCL13
- Chemokine (C-X-C) ligand 13
- CYR61/CCN1
- Cysteine-rich angiogenic inducer 61
- EAE
- Experimental autoimmune encephalomyelitis
- EDSS
- Expanded disability status scale
- FABP2
- Fatty acid-binding protein 2
- FDR
- False discovery rate
- HC
- Healthy controls
- HPA
- Hypothalamic-pituitary-adrenal
- MS
- Multiple sclerosis
- MSSS
- Multiple sclerosis severity score
- NEFL
- Neurofilament light chain
- NPX
- Normalized protein expression
- PEA
- Proximity extension assay
- PMS
- Progressive multiple sclerosis
- PPMS
- Primary progressive multiple sclerosis
- PTN
- Pleiotrophin
- RRMS
- Relapsing-remitting multiple sclerosis
- SPMS
- Secondary progressive multiple sclerosis
